AZD2389 + itraconazole

AZD2389 + itraconazole is a combination of two drugs: AZD2389, an orally available small molecule fibroblast activation protein (FAP) inhibitor developed by AstraZeneca, and itraconazole, an oral antifungal agent. AZD2389 acts as a FAP antagonist, targeting fibroblast activation protein to reduce fibrosis; it is under development for hepatic fibrosis and liver cirrhosis[1][7]. In clinical pharmacokinetic studies, itraconazole is used as a strong CYP3A4 inhibitor to assess drug-drug interactions and the metabolic profile of AZD2389 in healthy participants[9]. The combination is not a marketed therapy for a specific disease but is investigated in the context of PK/DDI studies to evaluate AZD2389 metabolism and safety when co-administered with itraconazole.